secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001558370-24-012223
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent Q2 net loss $39.3M; cash $298.7M funds into 2026; firmonertinib data at WCLC
--------------------------------------------------------------------------------

- Net loss for six months ended June 30, 2024 was $39.3M, compared to $33.7M in prior year period.
- Cash and cash equivalents $298.7M as of June 30, 2024; expected to fund operations into 2026.
- R&D expenses $38.8M (up from $30.6M) due to increased headcount and firmonertinib clinical costs.
- Interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC to be presented at WCLC presidential symposium on Sept 9, 2024.
- Entered ADC collaboration with Alphamab to discover and develop novel ADCs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000155837024012223/0001558370-24-012223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000155837024012223/avbp-20240814x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer